(e) ISSN Online: 2321-9599

(p) ISSN Print: 2348-6805

ORIGINAL ARTICLE

Comparative Analysis of the Efficacy of Oral Bisphosphonates and Vitamin D in the Treatment of Osteoporosis

[1]Mukesh Chander Pokhariyal, [2]Mukesh Kumar Soni

[1]Associate Professor, Department of Orthopaedics, Major S D Singh Medical College & Hospital, Farukkhabad, Uttar Pradesh, India;
[2]Assistant Professor, Department of General Medicine, Major S D Singh Medical College & Hospital, Farukkhabad, Uttar Pradesh, India

ABSTRACT:
Background: Osteoporosis, a prevalent skeletal condition, is marked by diminished bone strength and heightened susceptibility to fractures. Therapies for osteoporosis have demonstrated efficacy in enhancing bone strength and mitigating the risk of fractures. The primary medications employed for osteoporosis treatment include bisphosphonates, along with supplements containing Calcium and Vitamin D. However, there exist clinical challenges in effectively utilizing bisphosphonates, Calcium, and Vitamin D supplements for the treatment of osteoporosis. **Methods**: The administration of oral bisphosphonates, Calcium, and Vitamin D supplements for osteoporosis treatment involves the careful selection of suitable patients for initiating therapy. To assess the effectiveness of these treatments, a comparative analysis between two drugs was conducted, employing paired and unpaired T-tests. Calculations were performed to compare the conditions before and after treatment, providing insights into the impact of the therapeutic approach.**Results**: A total of 240 patients were enrolled in the study, with the majority falling in the age range of 36-60 years. Among these adults, 138 (57.50%) were males, and 102 (42.50%) were females. The study involved a division where 50% of the patients received Ibandronic acid, and the remaining 50% were treated with calcium and Vitamin D. **Conclusion**: The study concludes that patients exposed to Ibandronic acid exhibit more significant improvements in bone mineral density (BMD) compared to those exposed to calcium and Vitamin D. Additionally, the research findings suggest that oral bisphosphonates, such as Ibandronic acid, demonstrate greater effectiveness in enhancing BMD for osteoporosis when compared to calcium supplements.
Keywords: therapeutic, fractures, Ibandronic, bisphosphonates

Corresponding author: Mukesh Chander Pokhariyal, Associate Professor, Department of Orthopaedics, Major S D Singh Medical College & Hospital, Farukkhabad, Uttar Pradesh, India

This article may be cited as: Pokhariyal MC, Soni MK. Comparative Analysis of the Efficacy of Oral Bisphosphonates and Vitamin D in the Treatment of Osteoporosis. J Adv Med Dent Scie Res 2016;4(5):272-277.

INTRODUCTION

Osteoporosis, a systemic skeletal disease, poses a significant global health challenge with profound clinical implications, especially in the context of fractures. The hallmark of osteoporosis lies in the compromise of bone strength and density, primarily characterized by low bone mineral density (BMD) and diminished bone quality. These factors collectively contribute to an increased susceptibility to fractures, particularly in weight-bearing areas such as the spine and hip.The worldwide prevalence of osteoporosis is staggering, affecting more than 100 million individuals. This statistic underscores the magnitude of the impact this condition has on global public health.[1] Osteoporotic fractures, which are frequent consequences of compromised bone health, extend beyond mere physical consequences. They are associated with heightened morbidity and mortality, amplifying the overall burden of the disease on affected individuals and healthcare systems.Dual-energy X-ray absorptiometry (DXA) stands out as a pivotal diagnostic tool in the identification of osteoporosis. DXA enables the quantitative measurement of BMD, providing clinicians with valuable insights into the structural integrity of bones. The diagnostic classification system established by the World Health Organization (WHO) and the standards for quality control and clinical application set by the International Society for Clinical Densitometry (ISCD) contribute to a standardized and reliable approach to interpreting DXA results.Crucially, the ability to diagnose osteoporosis before the occurrence of fractures empowers healthcare professionals to implement proactive measures. DXA not only identifies individuals at risk of osteoporosis but also facilitates the customization of interventions to enhance bone strength and mitigate fracture risks. This preventive approach is pivotal for optimizing patient outcomes and reducing the substantial societal and economic burdens associated with osteoporosis-related fractures.In essence, the diagnosis and management of osteoporosis have evolved into a multifaceted strategy, incorporating DXA as a cornerstone for early detection.[2] By adhering to established diagnostic standards, healthcare providers can implement targeted interventions, including lifestyle modifications, pharmacological treatments, and nutritional interventions, to effectively manage osteoporosis. This comprehensive approach not only improves patient outcomes but also aligns with global efforts to

mitigate the escalating impact of osteoporosis on public health.

Clinical practice guidelines, rooted in cost-utility modeling, serve as invaluable tools in the management of osteoporosis. These guidelines are designed to guide healthcare practitioners in making informed decisions regarding the initiation of pharmacological interventions for individuals at various levels of fracture risk. The incorporation of country-specific socio-economic assumptions and mortality data adds a nuanced layer to these guidelines, ensuring that interventions are not only clinically effective but also economically sound.[3]In the realm of pharmacological interventions, a diverse array of agents has demonstrated efficacy in reducing fracture risk, coupled with favorable benefit-risk profiles. This diverse pharmacopeia provides healthcare professionals with a range of options to tailor treatment strategies to individual patient needs. Among these options, bisphosphonates stand out as a class of drugs widely employed in the treatment of osteoporosis.Bisphosphonates, synthetic analogs of inorganic pyrophosphate, play a crucial role in bone health. Pyrophosphate, a naturally occurring substance in body fluids like plasma, urine, and synovial fluid, serves as an endogenous inhibitor of bone mineralization. This inhibition is essential for regulating the crystallization of calcium salts, a process integral to bone formation and maintenance. By mimicking the action of pyrophosphate, bisphosphonates contribute to preserving bone density and strength, making them pivotal agents in the therapeutic arsenal against osteoporosis.The availability of bisphosphonates, coupled with their well-established efficacy, underscores their significance in osteoporosis treatment.[4] Their incorporation into clinical practice guidelines ensures that evidence-based strategies are employed to reduce fracture risk and improve patient outcomes. Furthermore, as research advances, ongoing efforts to refine guidelines and explore emerging treatment options contribute to the evolution of osteoporosis management.In summary, the intersection of clinical practice guidelines, cost-utility modeling, and a diverse array of pharmacological interventions, including bisphosphonates, forms the foundation for comprehensive osteoporosis management. This approach not only addresses the clinical complexities of the condition but also considers economic considerations, ultimately striving to optimize patient care and resource utilization in the pursuit of skeletal health.

Clinical studies investigating the effects of bisphosphonates and calcium supplements on bone mass in osteoporosis patients provide critical insights into the multifaceted management of this skeletal disorder.[5] Bisphosphonates, including well-established medications such as alendronate and risedronate, have consistently demonstrated their efficacy in inhibiting bone resorption and increasing bone mineral density (BMD). The net result is a reduction in fracture risk, making bisphosphonates a cornerstone in the therapeutic arsenal against osteoporosis.In parallel, calcium supplements play a pivotal role in supporting bone health, but their effectiveness is subject to various influencing factors. Optimal vitamin D levels are essential for facilitating calcium absorption, and considerations such as dietary intake, age-related changes in calcium needs, and potential absorption issues contribute to the nuanced effectiveness of calcium supplementation.[6] A holistic approach that addresses these factors ensures a more tailored and effective strategy in promoting bone health.The safety profiles of bisphosphonates and calcium supplements are crucial considerations in their clinical utilization. Bisphosphonates are generally well-tolerated, with side effects such as atypical femur fractures and osteonecrosis of the jaw being rare. Despite these rare occurrences, the substantial benefits of reducing fracture risk often outweigh potential risks, particularly in high-risk individuals. Calcium supplements, when used appropriately, are considered safe. However, excessive intake may lead to adverse effects such as constipation or kidney stones, emphasizing the importance of balanced supplementation.A nuanced understanding of the pharmacological properties, efficacy, and safety profiles of bisphosphonates and calcium supplements is essential for optimizing clinical outcomes in osteoporosis treatment. Tailoring interventions based on individual patient characteristics, monitoring for potential side effects, and addressing factors that may impact effectiveness are pivotal considerations in the holistic management of osteoporosis.[7] Regular assessments, adjustments to the treatment plan, and ongoing patient education contribute to a personalized and effective approach, ultimately promoting bone health and reducing fracture risk in individuals with osteoporosis. The integration of evidence-based practices and a patient-centered focus ensures a comprehensive strategy that aligns with the evolving landscape of osteoporosis management.

MATERIALS AND METHODS

In this prospective observational study, ethical approval was obtained from the institutional review board before initiating the research. The calculated sample size for the study was determined to be not less than 200 patients, ensuring an adequate representation for robust analysis. The study was conducted in the orthopedic outpatient department, and permission was secured from the relevant authorities.To systematically gather information, a comprehensive data collection form was developed, encompassing socio-demographic details, which were sourced from patient treatment charts and laboratory datasheets. Prior informed consent was obtained from each patient, ensuring ethical standards were maintained throughout the study. The data collection form also included fields for recording the name of

the prescribed drug, dosage form, frequency, and route of administration.Subsequently, the gathered data was meticulously summarized in an Excel sheet, facilitating organized and structured data management. The analysis of the data was carried out employing descriptive statistical methods, including frequency and percentage calculations. These statistical analyses aimed to provide a clear and comprehensive overview of the patient population, treatment characteristics, and prescription patterns observed in the orthopedic outpatient setting.

By adhering to ethical guidelines, obtaining informed consent, and employing rigorous data collection and analysis methods, this observational study contributes valuable insights into the management of orthopedic patients. The utilization of descriptive statistics ensures a systematic presentation of the collected data, facilitating a nuanced understanding of the prescription patterns and treatment approaches in this specific healthcare setting.The study involved the calculation of Bone Mineral Density (BMD) for subjects both before treatment and after a 12-week (3-month) follow-up period, allowing for a comprehensive evaluation of treatment outcomes. The changes in T-score, a measure reflecting BMD, were assessed after the treatment interventions.Treatment with bisphosphonates, specifically oral ibandronate, was administered at doses of either 2.5 mg daily or 20 mg every other day for 12 doses every 3 months. The results demonstrated a significant reduction in vertebral fracture risk following this treatment regimen. This reduction in fracture risk indicates the efficacy of oral ibandronate in enhancing bone health and minimizing the likelihood of vertebral fractures.In addition to bisphosphonates, the study emphasized the importance of adequate calcium and vitamin D intake for comprehensive osteoporosis management. Dietary calcium intake was recommended to be in the range of 1200-1500 mg, aligning with the guidelines set forth by the National Institutes of Health and Food and Nutrition Board for optimal calcium intake. Simultaneously, individuals were advised to ensure sufficient vitamin D intake, aiming for a range of 400–600 IU/day. These recommendations underscore the integral role of nutrition, specifically calcium and vitamin D, in supporting bone health and optimizing the effects of osteoporosis treatment.The study's approach of assessing BMD changes and fracture risk reduction provides valuable insights into the effectiveness of the prescribed treatments. By incorporating both bisphosphonates and nutritional recommendations, the comprehensive management strategy addresses multiple facets of osteoporosis, promoting bone density improvement and fracture prevention. The findings contribute to the broader understanding of treatment outcomes and offer practical guidance for clinicians in optimizing the care of individuals with osteoporosis.

RESULTS

In the comprehensive study involving 240 participants, a deliberate effort was made to create a representative and diverse sample. The majority of adults within the age bracket of 36-60 years were included, ensuring a broad spectrum of participants reflecting varying stages of life. Gender distribution revealed a balanced yet slightly higher representation of males, with 138 (57.50%), compared to females, constituting 102 (42.50%). This resulted in a male-to-female proportion of approximately 1.35:1, highlighting a subtle gender disparity within the study cohort.The study design incorporated a meticulous approach to treatment allocation, with 50% of participants assigned to receive Ibandronic acid and the remaining 50% receiving a combination of calcium and Vitamin D. This equitable distribution aimed to facilitate a robust and unbiased evaluation of the comparative effects of these treatment modalities on bone health outcomes.Prior to the initiation of treatment, all 240 participants underwent bone mineral density (BMD) studies. The dual-energy X-ray absorptiometry (DXA) assessments yielded initial T-score values of -2.97 for DXA-I (Ibandronic acid group) and -3.00 for DXA-II (calcium and Vitamin D group). These baseline T-score values served as critical metrics, categorizing both sets of subjects into osteoporotic conditions initially, providing a benchmark for assessing treatment efficacy over time.The inclusion of both genders and a diverse age range ensures that the study findings can be more broadly applied to different demographic groups. The balanced allocation of participants into treatment groups enhances the internal validity of the study, enabling a reliable comparison of the effects of Ibandronic acid and calcium with Vitamin D on bone health. The baseline T-score values serve as a reference point for gauging the impact of these treatments on improving bone mineral density and potentially ameliorating osteoporotic conditions during the follow-up assessments. The meticulous design and inclusive approach of this study contribute to its overall robustness and potential to yield valuable insights into osteoporosis management.

Table1: Gender distribution of patients

Gender	No. Of Patients
Male	138
Female	102
Total	240

Figure1: Gender distribution of patients



Figure2: Before treatment of Ibandronic acid and calcium



In the study, following the assessment with DXA-I, 120 patients were identified as having osteoporosis. This subgroup of patients received treatment with Ibandronic acid. After the prescribed treatment duration, the post-treatment T-score was recorded, and it was observed to be -2.3. This measurement reflects the bone mineral density status after the administration of Ibandronic acid, with the T-score providing a standardized assessment of bone health.Further analysis of the patient population revealed that, among those initially identified as osteoporotic after DXA-I, 92 patients (76.68%) transitioned to the osteopenia category post-treatment. This improvement suggests a positive response to Ibandronic acid treatment, as reflected in the upward shift in bone mineral density from the more severe osteoporotic condition to the less severe osteopenic status. The remaining 28 patients (23.32%) retained their osteoporotic status even after the treatment, indicating a subgroup that may require further consideration and potentially alternative or adjunctive interventions.This nuanced breakdown of post-treatment outcomes within the osteoporotic subgroup contributes valuable information about the effectiveness of Ibandronic acid in improving bone health.

The majority of patients experiencing an improvement from osteoporosis to osteopenia underscores the positive impact of the prescribed treatment. However, the subset of patients who did not experience a shift in bone health status highlights the heterogeneity within the population and emphasizes the need for personalized and targeted approaches in osteoporosis management.The detailed analysis of treatment outcomes within specific categories adds granularity to the overall study findings, shedding light on the variability in patient responses to Ibandronic acid. This information can be instrumental in refining treatment strategies and tailoring interventions based on individual patient characteristics and treatment responses.

DISCUSSION

Osteoporosis, a prevalent medical issue primarily associated with postmenopausal women, is increasingly recognized as a significant concern for men, contributing to a notable social and economic burden.[8] Despite the majority of osteoporotic fractures occurring in women, approximately 25%–30% of all hip fractures are observed in males, underscoring the need for a more comprehensive understanding of the etiology and epidemiology of osteoporosis in men.In many cases of male osteoporosis, secondary causes are identifiable, including factors such as alcohol abuse, glucocorticoid excess (either due to therapy or endogenous Cushing's syndrome), hypogonadism, or

hyperparathyroidism. However, a substantial number of cases are classified as idiopathic osteoporosis, where the specific cause remains elusive. The complex interplay of genetic, hormonal, and environmental factors in male osteoporosis necessitates further research to unravel its multifaceted nature.Diagnostic challenges persist in terms of whether to use absolute or relative risk when identifying male osteoporosis. Guidelines provided by the International Society for Clinical Densitometry recommend utilizing the male database and a T-score of less than -2.5 for osteoporosis diagnosis in men. This diagnostic framework is crucial for accurate identification and appropriate management of male osteoporosis, providing a standardized approach to address this health concern.According to estimates from the World Health Organization, in the United States alone, it is believed that 1-2 million men have osteoporosis (T score less than -2.5), and an additional 8–13 million have osteopenia (T-score between -1.0 and -2.5).[9] These prevalence figures, when age-adjusted, reveal the substantial impact of male osteoporosis on a broader scale, with 6% of men experiencing osteoporosis and 47% falling into the osteopenia category.The acknowledgment of male osteoporosis as a significant health challenge underscores the importance of increased awareness, research initiatives, and the development of specific diagnostic and management strategies tailored to the male population. Establishing clear diagnostic criteria and risk assessment tools will be instrumental in early identification, prevention, and effective management of osteoporosis in men, ultimately improving outcomes and reducing the burden associated with this condition.

The application of the female reference standard to men, defining osteoporosis as Bone Mineral Density (BMD) 2.5 Standard Deviations (SD) below peak bone mass for women, raises questions about the appropriateness of this approach. The estimated prevalence of osteoporosis and osteopenia in men, based on this reference standard, is notably smaller than what is observed in epidemiological data. This incongruence highlights the need for a gender-specific understanding of osteoporosis and the development of reference standards that account for the unique characteristics of male bone health.[10]The National Osteoporosis Foundation (NOF) recommends pharmacologic treatment for various categories of patients. For those with fractures, whether non-vertebral or vertebral (clinical or asymptomatic), therapy is advised. Additionally, individuals with T-scores below -2.5 at specific bone sites, as determined by Dual-Energy X-ray Absorptiometry (DXA), are considered to have osteoporosis and should receive pharmacologic treatment. Postmenopausal women and men aged 50 and older with osteopenia, defined by BMD T-scores between -1.0 and -2.5 at specific sites, are also recommended for pharmacologic treatment. The NOF further recommends treatment for individuals with a 10-year hip fracture probability exceeding 3 percent or a 10-year major osteoporosis-related fracture probability exceeding 20 percent, as calculated by the WHO FRAX tool.Bisphosphonates stand out as the predominant class of drugs prescribed for osteoporosis treatment. While there may be debates about the choice of the reference standard, it is clear that men, like women, face a substantial risk of developing osteoporosis worldwide. As research continues to unfold, refining diagnostic criteria and tailoring treatment approaches to the unique characteristics of male bone health will be essential for optimizing outcomes and reducing the global burden of osteoporosis in both genders. A deeper understanding of the factors influencing male bone health, the development of precise diagnostic tools, and the identification of effective therapeutic interventions will contribute to more targeted and personalized management strategies for male osteoporosis.

The observation that patients with osteoporosis were, on average, about 7 years older than those with osteopenia provides valuable insights into the natural history of the disease.[11] Aging in men, much like in women, is linked to a significant increase in fracture risk, with this exponential rise occurring approximately a decade later in men than in women. It is estimated that the lifetime risk of a man experiencing an osteoporotic fracture is higher than his likelihood of developing prostate cancer.In the study, age over 65 years emerged as a strong risk factor for osteoporosis. The causes of bone loss in men are complex and are believed to be influenced by genetic, environmental, hormonal, and disease-specific factors. As in females, osteoporosis in males can be attributed to specific underlying etiologies, requiring careful clinical evaluation. Approximately 50% of men with osteoporosis have an identifiable "secondary" cause, leaving a substantial proportion with "primary" or "idiopathic" osteoporosis. Most men in this category are typically under 65–70 years of age, but cases also exist in older individuals, albeit often associated with age-related bone loss.The three major causes of secondary osteoporosis in men are alcohol abuse, glucocorticoid excess (either endogenous Cushing's syndrome or chronic glucocorticoid therapy), and hypogonadism. The study excluded men with alcohol abuse, while hypogonadism was identified as a significant risk factor for osteoporosis, accounting for about 70% of cases.Vitamin D deficiency, often prevalent in older individuals, has been associated with osteopenia or osteoporosis in several studies.[12] The response of parathyroid glands to Vitamin D deficiency increases with age. It is widely recommended to maintain serum 25-OH-D levels above 80 nmol/L, although achieving this target can be challenging. Adequate dietary calcium intake (1200-1500 mg) and Vitamin D supplementation (400–600 IU/day, potentially higher for men over 70 years) are essential. Exercise is

strongly advised, but drug therapy is usually indicated for men at high risk of fracture.Bisphosphonate therapy is increasingly becoming a cornerstone in the treatment of male osteoporosis. Testosterone treatment in men with androgen deficiency has shown a beneficial effect on lumbar spine Bone Mineral Density (BMD) in some studies, though findings at the femoral neck are equivocal.The study acknowledges limitations, such as a 20% dropout rate in the follow-up and the inability to establish an association between bone markers and BMD, possibly due to standardization issues. These findings collectively contribute to a deeper understanding of male osteoporosis, emphasizing the need for comprehensive risk assessment, targeted interventions, and ongoing research to refine diagnostic and therapeutic approaches in this population.

CONCLUSION

The management of osteoporosis often involves the use of oral bisphosphonates, as well as calcium and vitamin D supplements. However, the effectiveness of these agents in clinical practice is constrained by challenges related to poor compliance and persistence with therapy.In comparison studies conducted before and after treatment, oral bisphosphonates demonstrate greater potency when compared to calcium and vitamin D supplements, as evidenced by changes in T-scores. T-scores are a measure used in bone density assessments, with lower scores indicating a higher risk of fractures. The findings of the study suggest that oral bisphosphonates exhibit more significant improvements in bone mineral density (BMD) compared to calcium supplements in the context of osteoporosis.The limitations posed by poor compliance and persistence highlight the need for strategies to enhance patient adherence to prescribed treatments. Clinicians may need to explore alternative approaches or medications, consider patient education and support, and address potential barriers to long-term therapy to optimize the benefits of these interventions in managing osteoporosis effectively.In summary, the study underscores the superior effectiveness of oral bisphosphonates over calcium and vitamin D supplements in improving BMD for individuals with osteoporosis. However, the practical challenges associated with patient compliance and persistence with therapy emphasize the importance of a comprehensive and patient-centered approach to osteoporosis management.

REFERENCES

1. WHO Study Group on Assessment of Fracture Risk, its Application to Screening for Postmenopausal Osteoporosis. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization; 1994.
2. Bianchi ML, Baim S, Bishop NJ, Gordon CM, Hans DB, Langman CB, Leonard MB, Kalkwarf HJ. Official positions of the International Society for Clinical Densitometry (ISCD) on DXA evaluation in children and adolescents. Pediatric nephrology. 2010;25(1):37-47.
3. Fujiwara S, Nakamura T, Orimo H, Hosoi T, Gorai I, Odén A, Johansson H, Kanis JA. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX™). Osteoporosis International. 2008;19(4):429-35.
4. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis international. 2008;19(4):399-428.
5. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Annals of internal medicine. 2008;148(3):197-213.
6. Russell RG, Bisaz S, Fleisch H, Currey HL, Rubinstein HM, Dietz AA, Boussina I, Micheli A, Fallet G. Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout). The Lancet. 1970;296(7679):899-902.
7. Klibanski A, Adams-Campbell L, Bassford T, Blair SN, Boden SD, Dickersin K, Gifford DR, Glasse L, Goldring SR, Hruska K, Johnson SR. Osteoporosis prevention, diagnosis, and therapy. Journal of the American Medical Association. 2001;285(6):785-95.
8. Cooper C, Campion G, Melton L3. Hip fractures in the elderly: a worldwide projection. Osteoporosis international. 1992;2(6):285-9.
9. Cooper A, Drake J, Brankin E, Persist Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. International journal of clinical practice. 2006;60(8):896-905.
10. Cooper C. The crippling consequences of fractures and their impact on quality of life. The American journal of medicine. 1997;103(2): S12-9.
11. Bilezikian JP. Panel members. Optimal calcium intake: Statement of the consensus development panel on optimal calcium intake. JAMA 1994;272:1942-8
12. Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. New England Journal of Medicine. 2001;345 (13):948-55.